Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15912086 | 0.73 | NCOA1 (0.43) | KMT2ANCOA1NCOA3MAPT | |
| SCHEMBL1684155 | 0.69 | — | — | |
| SCHEMBL4767840 | 0.65 | — | — | |
| SCHEMBL1760847 | 0.65 | — | — | |
| SCHEMBL30388054 | 0.65 | — | — | |
| SCHEMBL4985778 | 0.65 | — | — | |
| SCHEMBL5309066 | 0.65 | — | — | |
| SCHEMBL9779761 | 0.65 | — | — | |
| SCHEMBL31737160 | 0.65 | — | — | |
| SCHEMBL3239463 | 0.62 | EGFR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2752422-B1 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| EP-3074411-A2 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | Idenix Pharmaceuticals LLC (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015081133-A2 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2552931-B1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | GILEAD PHARMASSET LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752422-A1 | Stereoselective synthesis of phosphorus containing actives | Gilead Pharmasset LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | RNMT, NUDT1, NTPCR | KMT2A 528/4885CDC25B 2962/4885NCOA1 1646/4885 |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | KMT2A 4659/4885CDC25B 1721/4885NCOA1 3133/4885 |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | RNMT, NUDT1, NTPCR | KMT2A 528/4885CDC25B 2962/4885NCOA1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.